HEMATOLOGIC OUTCOMES AND DOSING PATTERNS IN ANEMIC PATIENTS WITH PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) SWITCHING FROM DARBEPOETIN ALFA (DARB) TO EPOETIN ALFA (EPO)

被引：0
|
作者：
Hura, Claudia [1 ]
Jackson, James [2 ]
Lunacsek, Orsolya [2 ]
Bailey, Robert A. [3 ]
McKenzie, R. Scott [3 ]
机构：
[1] San Antonio Kidney Dis Ctr, San Antonio, TX USA
[2] Xcenda LLC, Palm Harbor, FL USA
[3] Centocor Ortho Biotech Serv LLC, Horsham, PA USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2010年 / 55卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
133
引用
收藏
页码：A65 / A65
页数：1
相关论文
共 50 条
  • [21] Hemoglobin responses following darbepoetin alfa (Aranesp®) vs. epoetin alfa (Procrit®) administration in anemic chronic kidney disease (CKD) patients
    Sarac, E
    Veres, Z
    Schuler, E
    Tallum, S
    Gemmel, DJ
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V264 - V264
  • [22] Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease
    Chen, Han-Hsiang
    Tarng, Der-Cherng
    Lee, Kun-Feng
    Wu, Chih-Jen
    Chen, Yi-Chou
    JOURNAL OF NEPHROLOGY, 2008, 21 (04) : 543 - 549
  • [23] Hematologic outcomes and erythropoiesis-stimulating therapy costs in epoetin alfa (EPO)- and darbepoetin alfa (DARB)-treated cancer patients: Results of the dosing and outcomes study of erythropoiesis-stimulating therapies (DOSE registry).
    Chen, Er
    Peake, Cyrus
    Buscaino, Erminia
    Forlenza, Jamie
    Bookhart, Brahim
    McKenzie, Scott
    BLOOD, 2006, 108 (11) : 953A - 953A
  • [24] COST EFECTIVNESS OF DARBEPOETIN ALFA VERSUS EPOETIN ALFA IN THE MANAGEMENT OF ANEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE:HEALTH INSURANCE PERSPECTIVE
    Fouad, S.
    VALUE IN HEALTH, 2016, 19 (07) : A589 - A589
  • [25] COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN CHRONIC KIDNEY DISEASE AND CHEMOTHERAPY-INDUCED ANEMIA OUTPATIENTS
    Lafeuille, M. H.
    Bailey, R. A.
    Senbetta, M.
    McKenzie, R. S.
    Lefebvre, P.
    VALUE IN HEALTH, 2011, 14 (03) : A160 - A160
  • [26] COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN A CHRONIC KIDNEY DISEASE POPULATION TREATED IN THE HOSPITAL OUTPATIENT SETTING
    Vekeman, Francis
    McKenzie, R. Scott
    Lafeuille, Marie-Helene
    Bailey, Robert A.
    Piech, Catherine Tak
    Lefebvre, Patrick
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (04) : A78 - A78
  • [27] The economic impact of epoetin alfa (EPO) therapy on delaying time to dialysis in elderly patients with chronic kidney disease (CKD)
    Lefebvre, P
    Duh, M
    Mody, S
    Bookhart, B
    Piech, CT
    VALUE IN HEALTH, 2006, 9 (03) : A16 - A17
  • [28] Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis
    Barnett, AI
    Crémieux, PY
    PHARMACOTHERAPY, 2003, 23 (05): : 690 - 693
  • [29] Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis dialysis
    Hoggard, Jeffrey
    Crouch, Thomas
    McMurray, Stephen
    Levine, Michael
    Prathikanti, Radha
    Scarlata, Debra
    Audhya, Paul
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (10) : 2023 - 2030
  • [30] Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis
    McGowan, Tracy
    Vaccaro, Nicole M.
    Beaver, Jessica S.
    Massarella, Joseph
    Wolfson, Marsha
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (04): : 1006 - 1014
12345